Blood transfusion service in Poland in 2019

Streszczenie

Background: In this study we evaluated the basic aspects of the activity of the Polish Blood Transfusion Service (hereinafter referred to as Centers) in 2019. Materials and methods: Retrospective analysis of the 2019-data supplied by the Centers. Results: In 2019, blood and blood components were collected in 21 Polish Centers and 129 local collection sites as well as during 13 048 mobile collections. The overall number of blood donors was estimated at 590 893, the majority of which were non-remunerated donors (590 280 — including 40 738 responders to donation appeals), as well as 57 remunerated donors and 556 autologous donors. Most frequent were whole blood collections (1 202 079) and least frequent — granulocyte concentrate collections (94) and RBCs collections by apheresis (48 donations). Whole blood was collected mostly in local collection sites (45.25%), in Centers (28.75%) and mobile collection sites (26%). Most frequently prepared blood components were RBCs — 1 180 333 units) and fresh frozen plasma (FFP — 1 344 092 units, 21.42% dedicated for clinical use). Platelet concentrates (PCs) collected by apheresis amounted to 53 379 units and 81 905 were whole blood-derived. Additional processing methods (leukocyte depletion, irradiation) were more frequently applied to PCs (43.34% leukocyte-depleted, 0.04% irradiated, 54.63% both leukocyte-depleted and irradiated) than to RBCs (18.71% leukocyte-depleted, 0.06% irradiated, 9.17% both leukocytedepleted and irradiated). Pathogen reduction technologies were applied to 20.76% of FFP units issued for clinical use (transfusion) and 11.87% of PCs. In 2019 — for a variety of reasons — 14 013 units of whole blood, 32 798 units of RBCs, 49 285 units of FFP, 1334 units of cryoprecipitate, 4778 units of pooled PCs and 1279 of apheresis PCs were wasted. Conclusions: Our study data may be considered as starting point for assessment of the tendencies observed in the Polish blood transfusion service and may serve practical-benchmarking with benefit to the transfusion community as a whole.